Study Guide: Controlling Microbial Growth in the Body – Antimicrobial Drugs (Chapter 10)

Controlling Microbial Growth in the Body: Antimicrobial Drugs

Brief History of Antimicrobial Agents

Antimicrobial drugs have revolutionized the treatment of infectious diseases. Their development is closely tied to key discoveries in microbiology.

• Paul Ehrlich: Introduced the concept of selective toxicity and developed Salvarsan for syphilis.

• Alexander Fleming, Ernst Chain, Howard Florey: Discovered and developed penicillin, the first widely used antibiotic.

• Gerhard Domagk: Developed sulfanilamide, a pioneering sulfa drug.

• Selman Waksman & Albert Schatz: Isolated streptomycin from soil bacteria, effective against tuberculosis.

Selective toxicity is essential for antimicrobial drugs, ensuring they target pathogens with minimal harm to the host.

Mechanisms of Antimicrobial Action

Antimicrobial drugs act by targeting specific structures or processes in microbes. The five main mechanisms are:

• Inhibition of Cell Wall Synthesis: Prevents formation of peptidoglycan, leading to cell lysis. - Beta-lactams (e.g., penicillin, amoxicillin) block cross-linking of NAM subunits. - Vancomycin: Blocks alanine-alanine linkage in Gram-positive bacteria (narrow-spectrum). - Bacitracin: Blocks secretion of NAG and NAM. - Isoniazid, Ethambutol: Inhibit mycolic acid synthesis in Mycobacterium species.

• Inhibition of Protein Synthesis: Targets prokaryotic ribosomes (70S), disrupting translation. - Examples: Erythromycin, tetracycline.

• Disruption of Cytoplasmic Membranes: Forms channels in membranes, causing leakage. - Example: Polymyxin B (effective against Gram-negatives).

• Inhibition of Metabolic Pathways: Blocks unique metabolic reactions in pathogens. - Example: Sulfonamides (competitive inhibitors of para-aminobenzoic acid synthesis).

• Inhibition of Nucleic Acid Synthesis: Blocks DNA replication or RNA transcription. - Examples: Quinolones (ciprofloxacin, nalidixic acid), rifampin.

Antiviral agents target viral processes, such as uncoating (amantadine), release (oseltamivir), or protease activity (HIV drugs).

Spectrum of Activity

The spectrum of activity refers to the range of pathogens a drug can affect.

• Narrow-spectrum antibiotics: Target specific groups (e.g., only Gram-positive bacteria).

• Broad-spectrum antibiotics: Affect a wide range of bacteria (both Gram-positive and Gram-negative).

Efficacy depends on dosage, route of administration, and overall safety. Routes include topical, oral, intramuscular, and intravenous.

Clinical Testing and Efficacy

Several methods are used to test the effectiveness of antimicrobial drugs:

• Diffusion susceptibility tests (Kirby-Bauer): Measures zones of inhibition around antibiotic disks on agar plates.

• Minimum Inhibitory Concentration (MIC): Lowest concentration that inhibits visible growth.

• Minimum Bactericidal Concentration (MBC): Lowest concentration that kills the organism.

Consulting standard tables is necessary to interpret Kirby-Bauer results, as zone sizes vary by drug and organism.

Antibiotic Resistance

Resistance can be natural or acquired. Bacteria acquire resistance through:

• Mutation of chromosomal genes

• Acquisition of resistance genes via transformation, transduction, or conjugation (often on R-plasmids)

Mechanisms include:

• Enzyme production (e.g., beta-lactamase destroys penicillin)

• Reduced drug entry

• Altered drug targets

• Efflux pumps

Multi-drug resistance is common in hospital settings, leading to "superbugs." Avoiding resistance involves proper dosing, limiting use to bacterial infections, and combining drugs for synergistic effects.

Synergism and R-Plasmids

Synergism occurs when two drugs work together to enhance effectiveness. R-plasmids carry resistance genes and facilitate the spread of resistance.

• Example: Combining drugs to treat multidrug-resistant organisms.

Kirby-Bauer Test Example: The image below shows a petri dish with antibiotic disks, illustrating synergism between two antimicrobial agents. The enhanced zone of inhibition indicates increased effectiveness when drugs are combined.

Clinical Considerations

Adverse effects include toxicity (kidneys, liver, nervous system, fetus), allergic reactions, and disruption of normal microbiota (e.g., Clostridium difficile colitis). The therapeutic index is the ratio of tolerated dose to effective dose.

Summary Table: Mechanisms of Antimicrobial Action

Mechanism	Example Drugs	Target	Spectrum
Cell Wall Synthesis Inhibition	Penicillin, Vancomycin, Bacitracin	Peptidoglycan	Narrow/Broad
Protein Synthesis Inhibition	Erythromycin, Tetracycline	70S Ribosome	Broad
Membrane Disruption	Polymyxin B	Cytoplasmic Membrane	Narrow
Metabolic Pathway Inhibition	Sulfonamides	Folic Acid Synthesis	Broad
Nucleic Acid Synthesis Inhibition	Ciprofloxacin, Nalidixic Acid, Rifampin	DNA/RNA Polymerase	Broad

Key Equations

• Therapeutic Index: $\text{Therapeutic Index} = \frac{\text{Toxic Dose}}{\text{Effective Dose}}$

Additional info:

• Clinical trials progress from pre-clinical to Phase I-III, assessing safety, efficacy, and optimal administration.

• Synergism is visually demonstrated in the Kirby-Bauer test by larger zones of inhibition when drugs are combined.